Wells Fargo & Company Alaunos Therapeutics, Inc. Transaction History

Wells Fargo & Company

$407 Billion
Q2 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$0.04 - $0.13 $209 - $680	-5,236 Reduced 4.56%	109,713 $7,000
Q3 2023 Nov 13, 2023	SELL	$0.12 - $0.5 $3,663 - $15,266	-30,533 Reduced 20.99%	114,949 $14,000
Q2 2023 Aug 15, 2023	BUY	$0.43 - $0.65 $15,059 - $22,763	35,021 Added 31.7%	145,482 $74,000
Q1 2023 May 12, 2023	BUY	$0.46 - $0.81 $4,317 - $7,602	9,386 Added 9.29%	110,461 $69,000
Q4 2022 Feb 13, 2023	BUY	$0.5 - $261.0 $6,420 - $3.35 Million	12,841 Added 14.55%	101,075 $65,000
Q3 2022 Nov 14, 2022	BUY	$1.04 - $322.5 $36,821 - $11.4 Million	35,405 Added 67.02%	88,234 $150,000
Q2 2022 Aug 12, 2022	SELL	$0.41 - $1.24 $48,306 - $146,098	-117,821 Reduced 69.04%	52,829 $66,000
Q1 2022 May 16, 2022	SELL	$0.62 - $1.17 $90,766 - $171,285	-146,398 Reduced 46.18%	170,650 $111,000
Q4 2021 Feb 14, 2022	BUY	$1.09 - $1.89 $253,059 - $438,791	232,165 Added 273.51%	317,048 $345,000
Q3 2021 Nov 15, 2021	SELL	$1.44 - $2.73 $108,449 - $205,601	-75,312 Reduced 47.01%	84,883 $154,000
Q2 2021 Aug 16, 2021	SELL	$2.63 - $3.67 $83,094 - $115,953	-31,595 Reduced 16.47%	160,195 $423,000
Q1 2021 May 13, 2021	SELL	$2.82 - $5.6 $368,356 - $731,488	-130,623 Reduced 40.51%	191,790 $690,000
Q4 2020 Feb 09, 2021	BUY	$2.09 - $3.09 $81,035 - $119,808	38,773 Added 13.67%	322,413 $813,000
Q3 2020 Nov 05, 2020	BUY	$2.39 - $3.43 $66,406 - $95,302	27,785 Added 10.86%	283,640 $715,000
Q2 2020 Aug 13, 2020	BUY	$2.2 - $3.71 $218,853 - $369,067	99,479 Added 63.62%	255,855 $839,000
Q1 2020 May 14, 2020	BUY	$1.9 - $4.98 $297,114 - $778,752	156,376 New	156,376 $383,000

Others Institutions Holding TCRT

# of Institutions

Shares Held

92.6K

Call Options Held

Put Options Held

View Full List

About Alaunos Therapeutics, Inc.

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $443M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

More about TCRT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account